109 related articles for article (PubMed ID: 21174561)
1. Role of tyrosine kinase inhibitors in tumor immunology.
Nishioka Y; Aono Y; Sone S
Immunotherapy; 2011 Jan; 3(1):107-16. PubMed ID: 21174561
[TBL] [Abstract][Full Text] [Related]
2. Antitumour and immune-adjuvant activities of protein-tyrosine kinase inhibitors.
Seliger B; Massa C; Rini B; Ko J; Finke J
Trends Mol Med; 2010 Apr; 16(4):184-92. PubMed ID: 20304705
[TBL] [Abstract][Full Text] [Related]
3. The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies.
Ozao-Choy J; Ma G; Kao J; Wang GX; Meseck M; Sung M; Schwartz M; Divino CM; Pan PY; Chen SH
Cancer Res; 2009 Mar; 69(6):2514-22. PubMed ID: 19276342
[TBL] [Abstract][Full Text] [Related]
4. Myeloid-derived suppressor cells in human cancer.
Nagaraj S; Gabrilovich DI
Cancer J; 2010; 16(4):348-53. PubMed ID: 20693846
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic activity of sunitinib for Her2/neu induced mammary cancer in FVB mice.
Abe F; Younos I; Westphal S; Samson H; Scholar E; Dafferner A; Hoke TA; Talmadge JE
Int Immunopharmacol; 2010 Jan; 10(1):140-5. PubMed ID: 19833232
[TBL] [Abstract][Full Text] [Related]
6. β-glucan restores tumor-educated dendritic cell maturation to enhance antitumor immune responses.
Ning Y; Xu D; Zhang X; Bai Y; Ding J; Feng T; Wang S; Xu N; Qian K; Wang Y; Qi C
Int J Cancer; 2016 Jun; 138(11):2713-23. PubMed ID: 26773960
[TBL] [Abstract][Full Text] [Related]
7. Improving antitumor immune responses by circumventing immunoregulatory cells and mechanisms.
Lizée G; Radvanyi LG; Overwijk WW; Hwu P
Clin Cancer Res; 2006 Aug; 12(16):4794-803. PubMed ID: 16914564
[TBL] [Abstract][Full Text] [Related]
8. Are macrophages, myeloid derived suppressor cells and neutrophils mediators of local suppression in healthy and cancerous tissues in aging hosts?
Jackaman C; Nelson DJ
Exp Gerontol; 2014 Jun; 54():53-7. PubMed ID: 24291067
[TBL] [Abstract][Full Text] [Related]
9. Targeting immune suppressing myeloid-derived suppressor cells in oncology.
Kao J; Ko EC; Eisenstein S; Sikora AG; Fu S; Chen SH
Crit Rev Oncol Hematol; 2011 Jan; 77(1):12-9. PubMed ID: 20304669
[TBL] [Abstract][Full Text] [Related]
10. Glioma-derived galectin-1 regulates innate and adaptive antitumor immunity.
Verschuere T; Toelen J; Maes W; Poirier F; Boon L; Tousseyn T; Mathivet T; Gerhardt H; Mathieu V; Kiss R; Lefranc F; Van Gool SW; De Vleeschouwer S
Int J Cancer; 2014 Feb; 134(4):873-84. PubMed ID: 23929302
[TBL] [Abstract][Full Text] [Related]
11. Rapamycin Impairs Antitumor CD8+ T-cell Responses and Vaccine-Induced Tumor Eradication.
Chaoul N; Fayolle C; Desrues B; Oberkampf M; Tang A; Ladant D; Leclerc C
Cancer Res; 2015 Aug; 75(16):3279-91. PubMed ID: 26122844
[TBL] [Abstract][Full Text] [Related]
12. β-Glucan enhances antitumor immune responses by regulating differentiation and function of monocytic myeloid-derived suppressor cells.
Tian J; Ma J; Ma K; Guo H; Baidoo SE; Zhang Y; Yan J; Lu L; Xu H; Wang S
Eur J Immunol; 2013 May; 43(5):1220-30. PubMed ID: 23424024
[TBL] [Abstract][Full Text] [Related]
13. Chemotherapeutic targeting of cancer-induced immunosuppressive cells.
Alizadeh D; Larmonier N
Cancer Res; 2014 May; 74(10):2663-8. PubMed ID: 24778417
[TBL] [Abstract][Full Text] [Related]
14. Deciphering and reversing tumor immune suppression.
Motz GT; Coukos G
Immunity; 2013 Jul; 39(1):61-73. PubMed ID: 23890064
[TBL] [Abstract][Full Text] [Related]
15. Tolerogenic semimature dendritic cells induce effector T-cell hyporesponsiveness by the activation of antigen-specific CD4+ CD25+ T-regulatory cells.
Fu BM; He XS; Yu S; Hu AB; Ma Y; Wu LW; Tam NL; Huang JF
Exp Clin Transplant; 2009 Sep; 7(3):149-56. PubMed ID: 19715524
[TBL] [Abstract][Full Text] [Related]
16. Targeted therapies for solid tumors: current status and future perspectives.
Stoffel A
BioDrugs; 2010 Oct; 24(5):303-16. PubMed ID: 20649180
[TBL] [Abstract][Full Text] [Related]
17. The emerging understanding of myeloid cells as partners and targets in tumor rejection.
Broz ML; Krummel MF
Cancer Immunol Res; 2015 Apr; 3(4):313-9. PubMed ID: 25847968
[TBL] [Abstract][Full Text] [Related]
18. Sorafenib relieves cell-intrinsic and cell-extrinsic inhibitions of effector T cells in tumor microenvironment to augment antitumor immunity.
Chen ML; Yan BS; Lu WC; Chen MH; Yu SL; Yang PC; Cheng AL
Int J Cancer; 2014 Jan; 134(2):319-31. PubMed ID: 23818246
[TBL] [Abstract][Full Text] [Related]
19. CD4+Foxp3+ regulatory T cells converted by rapamycin from peripheral CD4+CD25(-) naive T cells display more potent regulatory ability in vitro.
Chen JF; Gao J; Zhang D; Wang ZH; Zhu JY
Chin Med J (Engl); 2010 Apr; 123(7):942-8. PubMed ID: 20497692
[TBL] [Abstract][Full Text] [Related]
20. Vitamin D3-mediated alterations to myeloid dendritic cell trafficking in vivo expand the scope of their antigen presenting properties.
Enioutina EY; Bareyan D; Daynes RA
Vaccine; 2007 Jan; 25(7):1236-49. PubMed ID: 17092617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
